Autoimmune Disease

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419215

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419215

North America and Europe Celiac Disease Market - Industry Trends and Forecast to 2031

PUBLISHED: December 1, 2023

PAGES: 317 Pages

DELIVERY TIME: Inquiry

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The North America celiac disease market is expected to reach USD 193,364.33 thousand by 2031 from USD 94,325.34 thousand in 2023, growing at a CAGR of 9.8% during the forecast period of 2024 to 2031.

The Europe celiac disease market is expected to reach USD 150,949.09 thousand by 2031 from USD 78,786.35 thousand in 2023, growing at a CAGR of 8.8% during the forecast period of 2024 to 2031.

Market Segmentation

North America and Europe celiac disease market, By Treatment type (Corticosteriods, Immunosuppressants, and Others), Disease Type (Classical Celiac Disease, Non-Classical Celiac Disease, Refractory Celiac Disease, Potential Celiac Disease, and Dermatitis Herpetiformis), Drug Type (Generics and Branded), Prescription Type (Prescription and Over The Counter), Dosage Form (Tablet, Capsules, Injection, and Other), Route of Administration (Oral, Intravenous, and Topical), Population Type (Children, Adults, and Geriatric), End User (Hospitals, Clinics, Diagnostic Centres, Home Care Settings, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2031.

Overview of North America and Europe Celiac Disease Market Dynamics

Driver
Increasing prevalence of celiac disease
Restraint
Complexity of celiac disease
Opportunity
Emerging biological therapies for celiac disease

Market Players

Some of the major market players operating in the North America and Europe celiac disease market are:

Takeda Pharmaceutical Company Limited
Salix Pharmaceuticals (subsidiary of Bausch Health Companies Inc.)
Tillotts Pharma AG
GSK plc.
ImmunogenX, Inc.
Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.)
Teva Pharmaceuticals USA, Inc.
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Amgen Inc.
AstraZeneca
Novartis AG
AdvaCare Pharma
ANOKION
Topas Therapeutics
Immunic Therapeutics
Equillium Bio.

1 INTRODUCTION 32

1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET 32
1.4 LIMITATIONS 34
1.5 MARKETS COVERED 34

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 DBMR TRIPOD DATA VALIDATION MODEL 39
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE FOR THE NORTH AMERICA CELIAC DISEASE MARKET 43
2.8 TREATMENT TYPE LIFELINE CURVE THE EUROPE CELIAC DISEASE MARKET 44
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.10 DBMR MARKET POSITION GRID 46
2.11 MARKET END USER COVERAGE GRID 48
2.12 VENDOR SHARE ANALYSIS 50
2.13 SECONDARY SOURCES 51
2.14 ASSUMPTIONS 51

3 EXECUTIVE SUMMARY 52

4 PREMIUM INSIGHTS 55

4.1 PESTAL ANALYSIS 57
4.2 PORTERS 5 FORCES 58
4.3 EPIDEMIOLOGY 59

5 PIPELINE ANALYSIS 60

6 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, REGULATORY FRAMEWORK 61

6.1 REGULATIONS IN NORTH AMERICA 61
- 6.1.1 U.S. 61
- 6.1.2 CANADA 61

6.2 REGULATIONS IN EUROPE 62
- 6.2.1 EUROPEAN UNION (EU) 62
- 6.2.2 U.K. 62

7 MARKET OVERVIEW 63

7.1 DRIVERS 65
- 7.1.1 INCREASING PREVALENCE OF CELIAC DISEASE 65
- 7.1.2 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS 66
- 7.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR CELIAC DISEASE TREATMENTS 67
- 7.1.4 GROWING AWARENESS ABOUT CELIAC DISEASE 68
7.2 RESTRAINTS 69
- 7.2.1 COMPLEXITY OF CELIAC DISEASE 69
- 7.2.2 LIMITED TREATMENT OPTIONS FOR CELIAC DISEASE 70
7.3 OPPORTUNITIES 71
- 7.3.1 EMERGING BIOLOGICAL THERAPIES FOR CELIAC DISEASE 71
- 7.3.2 RISING ADVANCEMENTS IN DIAGNOSTIC APPROACHES OF CELIAC DISEASE 72
- 7.3.3 STRATEGIC COLLABORATION FOR COMMERCIALIZATION OF NOVEL THERAPIES FOR CELIAC DISEASE 73
7.4 CHALLENGES 74
- 7.4.1 PATIENT ADHERENCE TO GLUTEN-FREE DIET 74
- 7.4.2 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR CELIAC DISEASE TREATMENT 74

8 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE 76

8.1 OVERVIEW 77
8.2 CORTICOSTERIODS 83
- 8.2.1 PREDNISONE 84
- 8.2.2 .BUDESONIDE 85
- 8.2.3 BETAMETHASONE 85
- 8.2.4 CLOBETASONE BUTYRATE 85
- 8.2.5 OTHERS 85
8.3 IMMUNOSUPPRESSANTS 85
- 8.3.1 AZATHIOPRINE 87
- 8.3.2 INFLIXIMAB 87
- 8.3.3 CYCLOSPORINE 87
- 8.3.4 CLADRIBINE 87
- 8.3.5 OTHERS 87
8.4 OTHERS 87

9 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE 88

9.1 OVERVIEW 89
9.2 REFRACTORY CELIAC DISEASE 95
- 9.2.1 TYPE I 96
- 9.2.2 TYPE II 96
9.3 DERMATITIS HERPETIFORMIS 96
9.4 POTENTIAL CELIAC DISEASE 96
9.5 CLASSICAL CELIAC DISEASE 97
9.6 NON-CLASSICAL CELIAC DISEASE 97

10 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE 98

10.1 OVERVIEW 99
10.2 GENERICS 105
10.3 BRANDED 105

11 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE 106

11.1 OVERVIEW 107
11.2 PRESCRIPTION 113
11.3 OVER THE COUNTER 113

12 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM 114

12.1 OVERVIEW 115
12.2 TABLET 121
12.3 CAPSULES 121
12.4 INJECTIONS 121
12.5 OTHER 122

13 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION 123

13.1 OVERVIEW 124
13.2 ORAL 130
- 13.2.1 TABLET 131
- 13.2.2 CAPSULES 131
- 13.2.3 OTHERS 131
13.3 INTRAVENOUS 131
13.4 TOPICAL 132

14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE 133

14.1 OVERVIEW 134
14.2 ADULTS 140
- 14.2.1 FEMALE 141
- 14.2.2 MALE 141
14.3 CHILDREN 141
14.4 GERIATRIC 141
- 14.4.1 FEMALE 142
- 14.4.2 MALE 142

15 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY END USER 143

15.1 OVERVIEW 144
15.2 HOSPITALS 150
15.3 CLINICS 150
15.4 HOME CARE SETTINGS 151
15.5 OTHERS 151

16 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL 152

16.1 OVERVIEW 153
16.2 HOSPITAL PHARMACY 159
16.3 RETAIL PHARMACY 159
16.4 ONLINE PHARMACY 160
16.5 OTHERS 160

17 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY GEOGRAPHY 161

17.1 NORTH AMERICA 161
- 17.1.1 U.S. 165
- 17.1.2 CANADA 171
- 17.1.3 MEXICO 178

17.2 EUROPE 184
- 17.2.1 GERMANY 188
- 17.2.2 FRANCE 194
- 17.2.3 ITALY 200
- 17.2.4 SPAIN 206
- 17.2.5 U.K. 212
- 17.2.6 SWITZERLAND 218
- 17.2.7 NETHERLANDS 224
- 17.2.8 RUSSIA 230
- 17.2.9 TURKEY 236
- 17.2.10 POLAND 242
- 17.2.11 SWEDEN 248
- 17.2.12 BELGIUM 254
- 17.2.13 DENMARK 260
- 17.2.14 FINLAND 266
- 17.2.15 NORWAY 272
- 17.2.16 REST OF EUROPE 278

18 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY LANDSCAPE 279

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 279

19 EUROPE CELIAC DISEASE MARKET: COMPANY LANDSCAPE 280

19.1 COMPANY SHARE ANALYSIS: EUROPE 280

20 SWOT ANALYSIS 281

21 COMPANY PROFILES 282

21.1 GSK PLC. 282
- 21.1.1 COMPANY SNAPSHOT 282
- 21.1.2 REVENUE ANALYSIS 283
- 21.1.3 PRODUCT PORTFOLIO 283
- 21.1.4 RECENT DEVELOPMENT 284
21.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 285
- 21.2.1 COMPANY SNAPSHOT 285
- 21.2.2 REVENUE ANALYSIS 285
- 21.2.3 PRODUCT PORTFOLIO 286
- 21.2.4 RECENT DEVELOPMENT 287

21.3 PFIZER INC. 288
- 21.3.1 COMPANY SNAPSHOT 288
- 21.3.2 REVENUE ANALYSIS 288
- 21.3.3 PRODUCT PORTFOLIO 289
- 21.3.4 RECENT DEVELOPMENT 289
21.4 TEVA PHARMACEUTICALS USA, INC. 290
- 21.4.1 COMPANY SNAPSHOT 290
- 21.4.2 REVENUE ANALYSIS 290
- 21.4.3 PRODUCT PORTFOLIO 291
- 21.4.4 RECENT DEVELOPMENT 293
21.5 NOVARTIS AG 294
- 21.5.1 COMPANY SNAPSHOT 294
- 21.5.2 REVENUE ANALYSIS 294
- 21.5.3 PRODUCT PORTFOLIO 295
- 21.5.4 RECENT DEVELOPMENT 295
21.6 ADVACARE PHARMA 296
- 21.6.1 COMPANY SNAPSHOT 296
- 21.6.2 PRODUCT PORTFOLIO 296
- 21.6.3 RECENT DEVELOPMENT 296
21.7 AMGEN INC. 297
- 21.7.1 COMPANY SNAPSHOT 297
- 21.7.2 REVENUE ANALYSIS 297
- 21.7.3 PRODUCT PORTFOLIO 298
- 21.7.4 RECENT DEVELOPMENT 298
21.8 ANOKION 299
- 21.8.1 COMPANY SNAPSHOT 299
- 21.8.2 PRODUCT PORTFOLIO 299
- 21.8.3 RECENT DEVELOPMENT 300
21.9 EQUILLIUM BIO. 301
- 21.9.1 COMPANY SNAPSHOT 301
- 21.9.2 PRODUCT PORTFOLIO 301
- 21.9.3 RECENT DEVELOPMENT 302
21.10 IMMUNIC THERAPEUTICS 303
- 21.10.1 COMPANY SNAPSHOT 303
- 21.10.2 PRODUCT PORTFOLIO 303
- 21.10.3 RECENT DEVELOPMENT 303
21.11 IMMUNOGENX, INC. 304
- 21.11.1 COMPANY SNAPSHOT 304
- 21.11.2 PRODUCT PORTFOLIO 304
- 21.11.3 RECENT DEVELOPMENT 304
21.12 SALIX PHARMACEUTICALS (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 305
- 21.12.1 COMPANY SNAPSHOT 305
- 21.12.2 REVENUE ANALYSIS OF PARENT COMPANY 305
- 21.12.3 PRODUCT PORTFOLIO 306
- 21.12.4 RECENT DEVELOPMENT 306
21.13 TAKEDA PHARMACEUTICAL COMPANY LIMITED 307
- 21.13.1 COMPANY SNAPSHOT 307
- 21.13.2 REVENUE ANALYSIS 307
- 21.13.3 PRODUCT PORTFOLIO 308
- 21.13.4 RECENT DEVELOPMENT 308
21.14 TILLOTTS PHARMA AG 310
- 21.14.1 COMPANY SNAPSHOT 310
- 21.14.2 PRODUCT PORTFOLIO 310
- 21.14.3 RECENT DEVELOPMENT 310
21.15 TOPAS THERAPEUTICS 311
- 21.15.1 COMPANY SNAPSHOT 311
- 21.15.2 PRODUCT PORTFOLIO 311
- 21.15.3 RECENT DEVELOPMENT 312

22 QUESTIONNAIRE 313

23 RELATED REPORTS 317

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET 60
TABLE 2 NORTH AMERICA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 83
TABLE 3 EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 83
TABLE 4 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 83
TABLE 5 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 84
TABLE 6 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 84
TABLE 7 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 84
TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 86
TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 86
TABLE 10 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 86
TABLE 11 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 86
TABLE 12 NORTH AMERICA CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND) 95
TABLE 13 EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND) 95
TABLE 14 NORTH AMERICA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 95
TABLE 15 EUROPE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 96
TABLE 16 NORTH AMERICA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 105
TABLE 17 EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 105
TABLE 18 NORTH AMERICA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 113
TABLE 19 EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 113
TABLE 20 NORTH AMERICA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 121
TABLE 21 EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 121
TABLE 22 NORTH AMERICA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 130
TABLE 23 EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 130
TABLE 24 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 130
TABLE 25 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND) 131
TABLE 26 NORTH AMERICA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 140
TABLE 27 EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 140
TABLE 28 NORTH AMERICA ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 140
TABLE 29 EUROPE ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 141
TABLE 30 NORTH AMERICA GERIATRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 142
TABLE 31 EUROPE GERAITRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 142
TABLE 32 NORTH AMERICA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 150
TABLE 33 EUROPE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 150
TABLE 34 NORTH AMERICA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 159
TABLE 35 EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 159
TABLE 36 NORTH AMERICA CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 164
TABLE 37 U.S. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 165
TABLE 38 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 165
TABLE 39 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 165
TABLE 40 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 166
TABLE 41 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 166
TABLE 42 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 166
TABLE 43 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 167
TABLE 44 U.S. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 167
TABLE 45 U.S. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 167
TABLE 46 U.S. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 168
TABLE 47 U.S. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 168
TABLE 48 U.S. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 168
TABLE 49 U.S. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 169
TABLE 50 U.S. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 169
TABLE 51 U.S. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 169
TABLE 52 U.S. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 169
TABLE 53 U.S. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 54 U.S. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 170
TABLE 55 U.S. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 170
TABLE 56 CANADA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 171
TABLE 57 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 171
TABLE 58 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 171
TABLE 59 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 172
TABLE 60 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 172
TABLE 61 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 172
TABLE 62 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 173
TABLE 63 CANADA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 173
TABLE 64 CANADA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 173
TABLE 65 CANADA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 174
TABLE 66 CANADA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 174
TABLE 67 CANADA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 174
TABLE 68 CANADA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 175
TABLE 69 CANADA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 175
TABLE 70 CANADA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 175
TABLE 71 CANADA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 176
TABLE 72 CANADA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 176
TABLE 73 CANADA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 176
TABLE 74 CANADA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 177
TABLE 75 MEXICO CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 178
TABLE 76 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 178
TABLE 77 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 178
TABLE 78 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 179
TABLE 79 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 179
TABLE 80 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 179
TABLE 81 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 180
TABLE 82 MEXICO CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 180
TABLE 83 MEXICO REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 180
TABLE 84 MEXICO CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 85 MEXICO CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 86 MEXICO CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 181
TABLE 87 MEXICO CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 182
TABLE 88 MEXICO ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 182
TABLE 89 MEXICO CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 182
TABLE 90 MEXICO ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 182
TABLE 91 MEXICO GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 183
TABLE 92 MEXICO CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 183
TABLE 93 MEXICO CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 183
TABLE 94 EUROPE CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 187
TABLE 95 GERMANY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 188
TABLE 96 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 188
TABLE 97 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 188
TABLE 98 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 189
TABLE 99 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 189
TABLE 100 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 189
TABLE 101 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 190
TABLE 102 GERMANY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 190
TABLE 103 GERMANY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 190
TABLE 104 GERMANY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 190
TABLE 105 GERMANY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 191
TABLE 106 GERMANY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 191
TABLE 107 GERMANY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 191
TABLE 108 GERMANY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 191
TABLE 109 GERMANY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 110 GERMANY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 111 GERMANY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 112 GERMANY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 192
TABLE 113 GERMANY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 193
TABLE 114 FRANCE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 194
TABLE 115 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 194
TABLE 116 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 194
TABLE 117 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 195
TABLE 118 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 195
TABLE 119 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 195
TABLE 120 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 196
TABLE 121 FRANCE CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 196
TABLE 122 FRANCE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 196
TABLE 123 FRANCE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 196
TABLE 124 FRANCE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 197
TABLE 125 FRANCE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 197
TABLE 126 FRANCE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 197
TABLE 127 FRANCE ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 198
TABLE 128 FRANCE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 129 FRANCE ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 130 FRANCE GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 198
TABLE 131 FRANCE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 199
TABLE 132 FRANCE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 199
TABLE 133 ITALY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 200
TABLE 134 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 200
TABLE 135 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 200
TABLE 136 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 201
TABLE 137 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 201
TABLE 138 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 201
TABLE 139 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 202
TABLE 140 ITALY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 141 ITALY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 142 ITALY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 143 ITALY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 203
TABLE 144 ITALY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 203
TABLE 145 ITALY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 203
TABLE 146 ITALY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 204
TABLE 147 ITALY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 204
TABLE 148 ITALY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 204
TABLE 149 ITALY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 204
TABLE 150 ITALY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 205
TABLE 151 ITALY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 205
TABLE 152 SPAIN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 206
TABLE 153 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 206
TABLE 154 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 206
TABLE 155 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 207
TABLE 156 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 207
TABLE 157 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 207
TABLE 158 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 208
TABLE 159 SPAIN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 208
TABLE 160 SPAIN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 208
TABLE 161 SPAIN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 208
TABLE 162 SPAIN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 209
TABLE 163 SPAIN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 209
TABLE 164 SPAIN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 209
TABLE 165 SPAIN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 210
TABLE 166 SPAIN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 167 SPAIN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 168 SPAIN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 169 SPAIN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 211
TABLE 170 SPAIN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 211
TABLE 171 U.K. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 172 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 173 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 212
TABLE 174 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 213
TABLE 175 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 213
TABLE 176 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 213
TABLE 177 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 214
TABLE 178 U.K. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 214
TABLE 179 U.K. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 214
TABLE 180 U.K. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 214
TABLE 181 U.K. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 215
TABLE 182 U.K. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 215
TABLE 183 U.K. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 215
TABLE 184 U.K. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 216
TABLE 185 U.K. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 216
TABLE 186 U.K. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 216
TABLE 187 U.K. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 216
TABLE 188 U.K. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 217
TABLE 189 U.K. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 217
TABLE 190 SWITZERLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 218
TABLE 191 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 218
TABLE 192 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 218
TABLE 193 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 219
TABLE 194 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 219
TABLE 195 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 219
TABLE 196 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 220
TABLE 197 SWITZERLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 220
TABLE 198 SWITZERLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 220
TABLE 199 SWITZERLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 220
TABLE 200 SWITZERLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 221
TABLE 201 SWITZERLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 221
TABLE 202 SWITZERLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 221
TABLE 203 SWITZERLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 222
TABLE 204 SWITZERLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 222
TABLE 205 SWITZERLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 222
TABLE 206 SWITZERLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 222
TABLE 207 SWITZERLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 223
TABLE 208 SWITZERLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 223
TABLE 209 NETHERLANDS CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 224
TABLE 210 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 224
TABLE 211 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 224
TABLE 212 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 225
TABLE 213 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 225
TABLE 214 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 225
TABLE 215 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 226
TABLE 216 NETHERLANDS CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 226
TABLE 217 NETHERLANDS REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 226
TABLE 218 NETHERLANDS CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 226
TABLE 219 NETHERLANDS CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 227
TABLE 220 NETHERLANDS CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 227
TABLE 221 NETHERLANDS CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 227
TABLE 222 NETHERLANDS ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 228
TABLE 223 NETHERLANDS CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 228
TABLE 224 NETHERLANDS ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 228
TABLE 225 NETHERLANDS GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 228
TABLE 226 NETHERLANDS CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 229
TABLE 227 NETHERLANDS CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 229
TABLE 228 RUSSIA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 230
TABLE 229 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 230
TABLE 230 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 230
TABLE 231 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 231
TABLE 232 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 231
TABLE 233 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 231
TABLE 234 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 232
TABLE 235 RUSSIA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 232
TABLE 236 RUSSIA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 232
TABLE 237 RUSSIA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 232
TABLE 238 RUSSIA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 233
TABLE 239 RUSSIA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 233
TABLE 240 RUSSIA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 233
TABLE 241 RUSSIA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 234
TABLE 242 RUSSIA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 234

TABLE 243 RUSSIA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 234
TABLE 244 RUSSIA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 234
TABLE 245 RUSSIA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 235
TABLE 246 RUSSIA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 235
TABLE 247 TURKEY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 236
TABLE 248 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 236
TABLE 249 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 236
TABLE 250 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 237
TABLE 251 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 237
TABLE 252 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 237
TABLE 253 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 238
TABLE 254 TURKEY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 238
TABLE 255 TURKEY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 238
TABLE 256 TURKEY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 238
TABLE 257 TURKEY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 239
TABLE 258 TURKEY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 239
TABLE 259 TURKEY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 239
TABLE 260 TURKEY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 240
TABLE 261 TURKEY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 240
TABLE 262 TURKEY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 240
TABLE 263 TURKEY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 240
TABLE 264 TURKEY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 241
TABLE 265 TURKEY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 241
TABLE 266 POLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 242
TABLE 267 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 242
TABLE 268 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 242
TABLE 269 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 243
TABLE 270 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 243
TABLE 271 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 243
TABLE 272 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 244
TABLE 273 POLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 244
TABLE 274 POLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 244
TABLE 275 POLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 244
TABLE 276 POLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 245
TABLE 277 POLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 245
TABLE 278 POLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 245
TABLE 279 POLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 246
TABLE 280 POLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 246
TABLE 281 POLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 246
TABLE 282 POLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 246
TABLE 283 POLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 247
TABLE 284 POLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 247
TABLE 285 SWEDEN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 248
TABLE 286 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 248
TABLE 287 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 248
TABLE 288 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 249
TABLE 289 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 249
TABLE 290 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 249
TABLE 291 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 250
TABLE 292 SWEDEN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 250
TABLE 293 SWEDEN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 250
TABLE 294 SWEDEN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 250
TABLE 295 SWEDEN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 251
TABLE 296 SWEDEN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 251
TABLE 297 SWEDEN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 251
TABLE 298 SWEDEN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 252
TABLE 299 SWEDEN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 252
TABLE 300 SWEDEN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 252
TABLE 301 SWEDEN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 252
TABLE 302 SWEDEN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 253
TABLE 303 SWEDEN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 253
TABLE 304 BELGIUM CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 254
TABLE 305 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 254
TABLE 306 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 254
TABLE 307 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 255
TABLE 308 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 255
TABLE 309 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 255
TABLE 310 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 256
TABLE 311 BELGIUM CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 256
TABLE 312 BELGIUM REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 256
TABLE 313 BELGIUM CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 256
TABLE 314 BELGIUM CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 257
TABLE 315 BELGIUM CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 257
TABLE 316 BELGIUM CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 257
TABLE 317 BELGIUM ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 258
TABLE 318 BELGIUM CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 258
TABLE 319 BELGIUM ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 258
TABLE 320 BELGIUM GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 258
TABLE 321 BELGIUM CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 259
TABLE 322 BELGIUM CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 259
TABLE 323 DENMARK CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 260
TABLE 324 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 260
TABLE 325 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 260
TABLE 326 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 261
TABLE 327 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 261
TABLE 328 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 261
TABLE 329 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 262
TABLE 330 DENMARK CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 262
TABLE 331 DENMARK REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 262
TABLE 332 DENMARK CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 262
TABLE 333 DENMARK CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 263
TABLE 334 DENMARK CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 263
TABLE 335 DENMARK CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 263
TABLE 336 DENMARK ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 264
TABLE 337 DENMARK CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 264
TABLE 338 DENMARK ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 264
TABLE 339 DENMARK GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 264
TABLE 340 DENMARK CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 265
TABLE 341 DENMARK CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 265
TABLE 342 FINLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 266
TABLE 343 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 266
TABLE 344 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 266
TABLE 345 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 267
TABLE 346 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 267
TABLE 347 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 267
TABLE 348 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 268
TABLE 349 FINLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 268
TABLE 350 FINLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 268
TABLE 351 FINLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 268
TABLE 352 FINLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 269
TABLE 353 FINLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 269
TABLE 354 FINLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 269
TABLE 355 FINLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 270
TABLE 356 FINLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 270
TABLE 357 FINLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 270
TABLE 358 FINLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 270
TABLE 359 FINLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 271
TABLE 360 FINLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 271
TABLE 361 NORWAY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 272
TABLE 362 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 272
TABLE 363 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS) 272
TABLE 364 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 273
TABLE 365 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 273
TABLE 366 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS) 273
TABLE 367 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT) 274
TABLE 368 NORWAY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND) 274
TABLE 369 NORWAY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 274
TABLE 370 NORWAY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND) 274
TABLE 371 NORWAY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND) 275
TABLE 372 NORWAY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 275
TABLE 373 NORWAY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND) 275
TABLE 374 NORWAY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND) 276
TABLE 375 NORWAY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND) 276
TABLE 376 NORWAY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 276
TABLE 377 NORWAY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND) 276
TABLE 378 NORWAY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 277
TABLE 379 NORWAY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND) 277
TABLE 380 REST OF EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND) 278

LIST OF FIGURES

FIGURE 1 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION 37
FIGURE 2 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DATA TRIANGULATION 39
FIGURE 3 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DROC ANALYSIS 40
FIGURE 4 NORTH AMERICA CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 41
FIGURE 5 EUROPE CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 41
FIGURE 6 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY RESEARCH ANALYSIS 42
FIGURE 7 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: INTERVIEW DEMOGRAPHICS 45
FIGURE 8 NORTH AMERICA CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID 46
FIGURE 9 EUROPE CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID 47
FIGURE 10 NORTH AMERICA CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID 48
FIGURE 11 EUROPE CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID 49
FIGURE 12 NORTH AMERICA CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS 50
FIGURE 13 EUROPE CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS 50
FIGURE 14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION 54
FIGURE 15 THE INCREASING PREVALENCE OF CELIAC DISEASE IS DRIVING THE GROWTH OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 55
FIGURE 16 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS IS DRIVING THE GROWTH OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 55
FIGURE 17 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031 56
FIGURE 18 CARTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031 56
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET 64
FIGURE 20 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023 77
FIGURE 21 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND) 78
FIGURE 22 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031) 78
FIGURE 23 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE 79
FIGURE 24 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023 80
FIGURE 25 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND) 81
FIGURE 26 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031) 81
FIGURE 27 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE 82
FIGURE 28 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023 89
FIGURE 29 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND) 90
FIGURE 30 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031) 90
FIGURE 31 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE 91
FIGURE 32 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023 92
FIGURE 33 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND) 93
FIGURE 34 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031) 93
FIGURE 35 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE 94
FIGURE 36 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2023 99
FIGURE 37 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND) 100
FIGURE 38 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031) 100
FIGURE 39 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE 101
FIGURE 40 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2023 102
FIGURE 41 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND) 103
FIGURE 42 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031) 103
FIGURE 43 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE 104
FIGURE 44 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023 107
FIGURE 45 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND) 108
FIGURE 46 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031) 108
FIGURE 47 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE 109
FIGURE 48 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023 110
FIGURE 49 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND) 111
FIGURE 50 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031) 111
FIGURE 51 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE 112
FIGURE 52 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023 115
FIGURE 53 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND) 116
FIGURE 54 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031) 116
FIGURE 55 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE 117
FIGURE 56 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023 118
FIGURE 57 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND) 119
FIGURE 58 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031) 119
FIGURE 59 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE 120
FIGURE 60 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023 124
FIGURE 61 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND) 125
FIGURE 62 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031) 125
FIGURE 63 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 126
FIGURE 64 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023 127
FIGURE 65 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND) 128
FIGURE 66 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031) 128
FIGURE 67 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 129
FIGURE 68 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023 134
FIGURE 69 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND) 135
FIGURE 70 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031) 135
FIGURE 71 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE 136
FIGURE 72 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023 137
FIGURE 73 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND) 138
FIGURE 74 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031) 138
FIGURE 75 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE 139
FIGURE 76 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2023 144
FIGURE 77 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND) 145
FIGURE 78 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031) 145
FIGURE 79 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE 146
FIGURE 80 EUROPE CELIAC DISEASE MARKET: BY END USER, 2023 147
FIGURE 81 EUROPE CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND) 148
FIGURE 82 EUROPE CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031) 148
FIGURE 83 EUROPE CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE 149
FIGURE 84 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023 153
FIGURE 85 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND) 154
FIGURE 86 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 154
FIGURE 87 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 155
FIGURE 88 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023 156
FIGURE 89 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND) 157
FIGURE 90 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 157
FIGURE 91 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 158
FIGURE 92 NORTH AMERICA CELIAC DISEASE MARKET: SNAPSHOT (2023) 162
FIGURE 93 EUROPE CELIAC DISEASE MARKET: SNAPSHOT (2023) 185
FIGURE 94 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%) 279
FIGURE 95 EUROPE CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%) 280

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ